𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial

✍ Scribed by Määttänen, L; Hakama, M; Tammela, T L J; Ruutu, M; Ala-Opas, M; Juusela, H; Martikainen, P; Stenman, U-H; Auvinen, A

Book ID
109999030
Publisher
Nature Publishing Group
Year
2007
Tongue
English
Weight
105 KB
Volume
96
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Test sensitivity of prostate-specific an
Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial
✍ Anssi Auvinen; Liisa Määttänen; Patrik Finne; Ulf-Håkan Stenman; Jussi Aro; Harr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB 👁 1 views

## Abstract We estimated the sensitivity of serum prostate‐specific antigen (PSA) as a screening test for prostate cancer in the Finnish randomised, population‐based prostate cancer screening trial. The study population consisted of 80,458 men aged 55–67 years identified from the national populatio

Prostate-specific antigen in screening o
Prostate-specific antigen in screening of prostate cancer
✍ Dr. T. Ming Chu 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 467 KB 👁 1 views

Prostate-specific antigen (PSA) is a wellcharacterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurren

Evaluation of serum prostate-specific an
Evaluation of serum prostate-specific antigen in urologic cancers
✍ Toshimi Takeuchi; Manabu Kuriyama; Shigeru Fujihiro; Yoshinori Fujimoto; Manabu 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract Serum prostate‐specific antigen (PA), a new tumor marker of prostate cancer, was evaluated with an enzyme immunoassay (EIA) in various urologic cancer patients and benign prostatic diseases in Japanese. Sera of prostate cancer patients before treatment (n = 27) revealed a range of PA co